This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Eli Lilly & Company

Drug Names(s): Cefaclor; cefaclorum

Description: Ceclor is a semisynthetic, broad-spectrum second generation cephalosporin antibiotic for oral administration. Compared to first generation cephalosporins such as Keflex, second generation cephalosporins exhibit better Gram-(-) activity and somewhat weaker Gram-(+) activity. They are more stable to Gram-(-) beta lactamases. They exhibit good activity against many enteric Gram-(-) rods, Haemophilus influenzae, and Neisseria gonorrheae; moderate activity against streptococci and staphylococci; and poor activity against enterococci, methacillin resistant Staphylococcus aureus and Psuedomonas.

Ceclor News

Pink Sheet Lilly's cefalexin

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug